1. Home
  2. ALLO vs MVF Comparison

ALLO vs MVF Comparison

Compare ALLO & MVF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • MVF
  • Stock Information
  • Founded
  • ALLO 2017
  • MVF 1988
  • Country
  • ALLO United States
  • MVF United States
  • Employees
  • ALLO N/A
  • MVF N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • MVF Investment Bankers/Brokers/Service
  • Sector
  • ALLO Health Care
  • MVF Finance
  • Exchange
  • ALLO Nasdaq
  • MVF Nasdaq
  • Market Cap
  • ALLO 427.7M
  • MVF 438.5M
  • IPO Year
  • ALLO 2018
  • MVF N/A
  • Fundamental
  • Price
  • ALLO $2.17
  • MVF $7.29
  • Analyst Decision
  • ALLO Strong Buy
  • MVF
  • Analyst Count
  • ALLO 10
  • MVF 0
  • Target Price
  • ALLO $10.06
  • MVF N/A
  • AVG Volume (30 Days)
  • ALLO 9.8M
  • MVF 162.8K
  • Earning Date
  • ALLO 03-13-2025
  • MVF 01-01-0001
  • Dividend Yield
  • ALLO N/A
  • MVF 4.11%
  • EPS Growth
  • ALLO N/A
  • MVF N/A
  • EPS
  • ALLO N/A
  • MVF N/A
  • Revenue
  • ALLO $43,000.00
  • MVF N/A
  • Revenue This Year
  • ALLO N/A
  • MVF N/A
  • Revenue Next Year
  • ALLO N/A
  • MVF N/A
  • P/E Ratio
  • ALLO N/A
  • MVF N/A
  • Revenue Growth
  • ALLO 26.47
  • MVF N/A
  • 52 Week Low
  • ALLO $1.32
  • MVF $5.85
  • 52 Week High
  • ALLO $5.78
  • MVF $7.19
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 55.14
  • MVF 55.88
  • Support Level
  • ALLO $1.32
  • MVF $7.14
  • Resistance Level
  • ALLO $3.78
  • MVF $7.37
  • Average True Range (ATR)
  • ALLO 0.36
  • MVF 0.07
  • MACD
  • ALLO 0.10
  • MVF 0.00
  • Stochastic Oscillator
  • ALLO 34.55
  • MVF 65.22

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About MVF Blackrock MuniVest Fund Inc.

Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.

Share on Social Networks: